The most effective weight loss medications currently available are the injectable GLP-1 drugs, with tirzepatide (Zepbound) and semaglutide (Wegovy) producing significantly more weight loss than any oral option. In clinical trials, these medications help people lose 15% to 22% of their body weight over about a year, a level of results that was previously only achievable through surgery.
But “best” depends on more than raw numbers. Cost, how you feel on the medication, whether you can stay on it long-term, and what happens when you stop all matter. Here’s how the leading options compare.
The Top-Tier Injectables: Zepbound and Wegovy
Tirzepatide (brand name Zepbound) and semaglutide (brand name Wegovy) are both once-weekly injections and represent the current gold standard for prescription weight loss. They work by mimicking natural gut hormones that signal fullness to your brain. Receptors for these hormones exist throughout the hypothalamus and brainstem, and when activated, they suppress appetite at a neurological level. You don’t just resist cravings; you genuinely feel less hungry and get full faster.
Semaglutide targets one hormone pathway (GLP-1). In the STEP UP trial, the higher 7.2 mg dose produced an average weight loss of 18.7% of body weight, compared to 3.9% for placebo. The standard 2.4 mg dose, which is the currently approved Wegovy formulation, produced 15.6% weight loss in the same trial.
Tirzepatide targets two hormone pathways (GLP-1 and GIP), which appears to give it an edge. In the SURMOUNT trials that led to its approval, tirzepatide at its highest dose produced average weight loss in the range of 20% to 22% of body weight over 72 weeks. Head-to-head data is still limited, but the available evidence puts tirzepatide slightly ahead on raw weight loss numbers.
Both medications are self-administered with a small pen injector, typically in the thigh or abdomen. Doses start low and increase gradually over several weeks to minimize side effects.
How They Actually Feel to Use
The most common side effects of both tirzepatide and semaglutide are gastrointestinal: nausea, constipation, and abdominal discomfort. These are directly tied to how the drugs work, since they slow the movement of food through your digestive system. For most people, nausea is worst during dose increases and fades over time. Some people barely notice it; others find it persistent enough to affect daily life.
Rare but more serious risks exist. Compared to users of older weight loss drugs, people taking GLP-1 medications have a higher rate of pancreatitis, bowel obstruction, and gastroparesis (severely delayed stomach emptying). These remain uncommon in absolute terms, but they’re worth knowing about, especially if you already have a history of digestive problems.
There’s also an FDA warning against using these drugs if you have a personal or family history of medullary thyroid cancer or a condition called MEN2 (multiple endocrine neoplasia type 2). This comes from rodent studies that showed increased thyroid tumors, though recent research from the Mayo Clinic suggests the link in humans may reflect detection bias rather than true causation. The warning remains in place regardless.
Oral Medications: Less Effective but Still Useful
Not everyone wants or can use an injectable. Two FDA-approved oral options offer meaningful, if more modest, results.
Phentermine-topiramate (brand name Qsymia) combines a stimulant that suppresses appetite with an anti-seizure drug that also reduces hunger. In a 56-week trial of overweight and obese adults, the higher dose produced an average weight loss of 9.8% of body weight, and 70% of participants lost at least 5%. Nearly half lost 10% or more. That’s a real result, even if it’s roughly half of what the injectables achieve.
Naltrexone-bupropion (brand name Contrave) works through a different mechanism, targeting reward pathways in the brain that drive cravings. It typically produces more modest weight loss, in the range of 5% to 8% of body weight. It can be a reasonable choice for people who also deal with food-related compulsive behavior, or for those who can’t tolerate other options.
Both oral medications carry their own side effect profiles. Phentermine-topiramate can cause tingling in the hands and feet, dry mouth, and cognitive fogginess. Contrave may increase heart rate and can cause nausea, particularly in the first few weeks.
What Happens When You Stop
This is the part most people don’t hear about until it affects them. A systematic review published in The Lancet’s eClinicalMedicine found that one year after stopping a GLP-1 medication, people regained 60% of the weight they had lost during treatment. The trajectory doesn’t stop there: weight regain is estimated to plateau at roughly 75% of the lost weight over longer periods.
The half-life of weight regain is about 23 weeks, meaning you’ll typically regain half the weight within five to six months of stopping. This doesn’t mean the medications failed. It means obesity, for many people, is a chronic condition that requires ongoing treatment, much like blood pressure medication. If you stop taking it, the underlying biology reasserts itself.
This has practical implications for how you think about cost and commitment. If you’re considering one of these medications, the question isn’t just “can I afford it this month?” but “can I sustain this for years?”
Cost and Access Realities
The list price for Wegovy and Zepbound runs over $1,000 per month without insurance. Coverage varies widely. Most insurance plans that do cover these medications require prior authorization, which typically means documenting a BMI of 30 or higher (or 27 with at least one weight-related condition like high blood pressure or type 2 diabetes). Some plans exclude weight loss drugs entirely.
The oral options tend to be significantly cheaper, particularly because generic versions of phentermine and topiramate are available separately (though the brand-name combination, Qsymia, is still priced at a premium). For people without insurance coverage for injectables, the oral route may be the most practical starting point.
What’s Coming Next
The next generation of weight loss drugs is already in late-stage clinical trials. CagriSema, developed by Novo Nordisk, combines semaglutide with cagrilintide, which mimics a different satiety hormone called amylin. Phase 3 trials are underway with treatment periods extending beyond two years. Retatrutide, from Eli Lilly, targets three hormone receptors simultaneously and showed weight loss exceeding 24% in a Phase 2 trial. Both could reach the market within the next few years.
These pipeline drugs suggest the ceiling for medication-based weight loss hasn’t been reached yet. But for now, the choice comes down to tirzepatide and semaglutide as the most effective options, with oral alternatives for those who need a different approach. Tirzepatide edges ahead on average weight loss in trials, making Zepbound the closest thing to a single “best” answer, though individual responses vary and the right medication depends on your body, your budget, and what you can commit to long-term.